{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:55:04Z","timestamp":1788998104466,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115653","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:37:52Z","timestamp":1760567872000},"page":"115653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer"],"prefix":"10.1016","volume":"167","author":[{"given":"Yun Jung","family":"Um","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwook","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Yung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hyung","family":"Yum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsik","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Sun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Duk","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115653_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2023.07.058","article-title":"Molecular and structural basis of TIGIT: Nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy","volume":"677","author":"Ganguli","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124427","article-title":"TIGIT signaling restores suppressor function of Th1 Tregs","volume":"4","author":"Lucca","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.intimp.2025.115653_bb0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.intimp.2025.115653_bb0025","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/eji.201545480","article-title":"TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals","volume":"45","author":"Wang","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13089","article-title":"Human CD4+ and CD8+ T lymphocyte subpopulations have significantly different surface expression patterns of CD226 and TIGIT molecules","volume":"94","author":"\u0160unina","year":"2021","journal-title":"Scand. J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115653_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2025.115653_bb0050","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","article-title":"Anti-TIGIT antibody Tiragolumab alone or with Atezolizumab in patients with advanced solid tumors: a phase 1a\/1b nonrandomized controlled trial","volume":"9","author":"Kim","year":"2023","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.115653_bb0065","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric Cancer: MORPHEUS phase Ib\/II umbrella randomized study platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.intimp.2025.115653_bb0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115653_bb0075","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1111\/cas.15890","article-title":"Multifaced roles of desmoplastic reaction and fibrosis in pancreatic cancer progression: current understanding and future directions","volume":"114","author":"Sato","year":"2023","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2025.115653_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157168","article-title":"Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers","volume":"132","author":"Donahue","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115653_bb0090","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31098","article-title":"Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins","volume":"7","author":"Martinko","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.intimp.2025.115653_bb0095","series-title":"and H","first-page":"e2415196","author":"Tao","year":"2025"},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1470-2045(22)00783-5","article-title":"Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study","volume":"24","author":"Wang","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2025.115653_bb0105","article-title":"Tumor mutational burden in real-world patients with pancreatic Cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115653_bb0110","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","article-title":"The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer","volume":"39","author":"Freed-Pastor","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115653_bb0115","doi-asserted-by":"crossref","first-page":"35848","DOI":"10.1038\/srep35848","article-title":"Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma","volume":"6","author":"Bailey","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0120","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2025.115653_bb0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nature cancer."},{"issue":"4","key":"10.1016\/j.intimp.2025.115653_bb0130","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcmgh.2019.07.008","article-title":"Peripheral blood T-cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines","volume":"8","author":"Xu","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"50","key":"10.1016\/j.intimp.2025.115653_bb0140","doi-asserted-by":"crossref","first-page":"E11731","DOI":"10.1073\/pnas.1814052115","article-title":"CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1","volume":"115","author":"Du","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0145","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","article-title":"Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation","volume":"36","author":"Rao","year":"2012","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2025.115653_bb0150","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-18-3107","article-title":"Eomes+ T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia","volume":"79","author":"Jia","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115653_bb0155","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpba.2014.09.007","article-title":"Development and validation of a novel SPR-based assay principle for bispecific molecules","volume":"102","author":"Gassner","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J. Hematother. Stem Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-021-01365-z","article-title":"CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell\u2013mediated cytotoxicity","volume":"45","author":"Park","year":"2022","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.intimp.2025.115653_bb0170","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic'for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"23","key":"10.1016\/j.intimp.2025.115653_bb0175","doi-asserted-by":"crossref","first-page":"12919","DOI":"10.3390\/ijms222312919","article-title":"Combined blockade of TIGIT and CD39 or A2AR enhances NK-92 cell-mediated cytotoxicity in AML","volume":"22","author":"Brauneck","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precision Oncology."},{"issue":"9","key":"10.1016\/j.intimp.2025.115653_bb0185","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41588-022-01157-1","article-title":"Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer","volume":"54","author":"Cui Zhou","year":"2022","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0190","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12967-022-03670-7","article-title":"Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies","volume":"20","author":"Giampietri","year":"2022","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.intimp.2025.115653_bb0195","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/2159-8290.CD-20-0841","article-title":"Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome","volume":"11","author":"Liudahl","year":"2021","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.intimp.2025.115653_bb0200","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1158\/0008-5472.CAN-23-2455","article-title":"Fc-silent anti-TIGIT antibodies potentiate antitumor immunity without depleting regulatory T cells","volume":"84","author":"Piovesan","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.12717\/DR.2019.23.2.079","article-title":"T lymphocyte development and activation in humanized mouse model","volume":"23","author":"Lee","year":"2019","journal-title":"Development & Reproduction."},{"issue":"3","key":"10.1016\/j.intimp.2025.115653_bb0210","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1096\/fj.201700740R","article-title":"Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy","volume":"32","author":"Wang","year":"2017","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.intimp.2025.115653_bb0215","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1172\/JCI67175","article-title":"Opposing chemokine gradients control human thymocyte migration in situ","volume":"123","author":"Halkias","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2025.115653_bb0220","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2005-02-0516","article-title":"Development of functional human blood and immune systems in NOD\/SCID\/IL2 receptor \u03b3 chainnull mice","volume":"106","author":"Ishikawa","year":"2005","journal-title":"Blood"},{"issue":"44","key":"10.1016\/j.intimp.2025.115653_bb0225","doi-asserted-by":"crossref","first-page":"E6020","DOI":"10.1073\/pnas.1519118112","article-title":"Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus","volume":"112","author":"Brugman","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2025.115653_bb0230","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.immuni.2020.09.013","article-title":"CD226 throttles up CD8+ T cell antitumor activity","volume":"53","author":"Philip","year":"2020","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.intimp.2025.115653_bb0235","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","article-title":"TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat Cancer."},{"issue":"8","key":"10.1016\/j.intimp.2025.115653_bb0240","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"issue":"7050","key":"10.1016\/j.intimp.2025.115653_bb0245","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nature03843","article-title":"T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand","volume":"436","author":"Choudhuri","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0250","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bpj.2023.12.012","article-title":"Computational simulations of bispecific T cell engagers by a multiscale model","volume":"123","author":"Su","year":"2024","journal-title":"Biophys. J."},{"issue":"22","key":"10.1016\/j.intimp.2025.115653_bb0255","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425781122","article-title":"Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency","volume":"122","author":"Leithner","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"534","key":"10.1016\/j.intimp.2025.115653_bb0260","doi-asserted-by":"crossref","first-page":"eaax1315","DOI":"10.1126\/scitranslmed.aax1315","article-title":"Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies","volume":"12","author":"Santich","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0265","first-page":"34","article-title":"Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells, Cancer immunology","volume":"73","author":"Gurrea-Rubio","year":"2024","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.intimp.2025.115653_bb0270","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.autrev.2017.12.004","article-title":"Clinical and experimental evidence for targeting CD6 in immune-based disorders","volume":"17","author":"Consuegra-Fernandez","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2025.115653_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009416","article-title":"Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK\/STAT signaling pathway","volume":"12","author":"Huang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0285","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cncr.22402","article-title":"Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors","volume":"109","author":"Beckman","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2025.115653_bb0290","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.0022-202X.2005.23657.x","article-title":"Resistance to activation-induced cell death and bystander cytotoxicity via the Fas\/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas","volume":"124","author":"Ni","year":"2005","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115653_bb0295","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/0008-5472.CAN-08-4631","article-title":"Lack of T-cell receptor\u2013induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death","volume":"69","author":"Klemke","year":"2009","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115653_bb0300","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri2115","article-title":"Life and death in peripheral T cells","volume":"7","author":"Krammer","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0305","doi-asserted-by":"crossref","first-page":"23401","DOI":"10.1038\/s41598-024-73712-1","article-title":"MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells","volume":"14","author":"Toyoda","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00006676-199703000-00011","article-title":"Overexpression of intercellular adhesion molecule-1 (ICAM-1) in pancreatic adenocarcinoma in comparison with normal pancreas","volume":"14","author":"Shimoyama","year":"1997","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.intimp.2025.115653_bb0315","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/cdd.2009.206","article-title":"Granzymes in cancer and immunity","volume":"17","author":"Cullen","year":"2010","journal-title":"Cell Death & Differentiation."},{"issue":"20","key":"10.1016\/j.intimp.2025.115653_bb0320","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199205143262006","article-title":"The extracellular actin-scavenger system and actin toxicity","volume":"326","author":"Lee","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115653_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0330","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/bloodadvances.2020003149","article-title":"Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer","volume":"5","author":"Hisada","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.intimp.2025.115653_bb0335","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2025.115653_bb0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molimm.2015.07.005","article-title":"Identifying the ERAD ubiquitin E3 ligases for viral and cellular targeting of MHC class I","volume":"68","author":"Van den Boomen","year":"2015","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115653_bb0345","doi-asserted-by":"crossref","first-page":"10445","DOI":"10.1038\/s41598-017-10403-0","article-title":"Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells","volume":"7","author":"Zitti","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115653_bb0350","doi-asserted-by":"crossref","first-page":"1150803","DOI":"10.3389\/fimmu.2023.1150803","article-title":"CD226 identifies functional CD8+ T cells in the tumor microenvironment and predicts a better outcome for human gastric cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.intimp.2025.115722","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000}},{"DOI":"10.1016\/j.intimp.2025.115722","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:36:01Z","timestamp":1765456561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925016443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":70,"alternative-id":["S1567576925016443"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115653","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115653"}}